Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
U0267 Foam · 1 trial · 1 indication
Assessment (on a scale of 0 to 4) was made as a visual average of all lesions, except those on the face/scalp. 0=clear; minor residual discoloration; no erythema/scaling/plaque thickness (PT). 1=almost clear; occasional fine scale/faint erythema/barely perceptible PT. 2=mild; fine scales predominate; light red coloration/mild PT. 3=moderate; coarse scales predominate; moderate red coloration/moderate PT. 4=severe; thick tenacious scale predominates; deep red coloration/severe PT. Treatment success=ISGA score 0 or 1, and a minimum improvement in the ISGA score of 2 grades from BL to week 8.
| Arm | Type | Description |
|---|---|---|
| U0267 foam | EXPERIMENTAL | U0267 is a vitamin D3 analog (calcipotriene) foam. It is applied twice a day for 8 weeks to psoriasis lesions on the body. |
| Vehicle foam | PLACEBO_COMPARATOR | Vehicle foam is the same as the U0267 foam except that it does not have the active ingredient. It is applied twice a day for 8 weeks to psoriasis lesions on the body. |
| Name | Type | Description |
|---|---|---|
| U0267 Foam | DRUG | All treatments will be administered topically twice daily (morning and evening) for 8 weeks to areas affected with psoriasis (excluding face and scalp). |
| Vehicle foam | DRUG | All treatments will be administered topically twice daily (morning and evening) for 8 weeks to areas affected with psoriasis (excluding face and scalp). |
Inclusion Criteria: * Male or female subjects at least 12 years old and in good general health. * Mild to moderate plaque-type psoriasis Exclusion Criteria: * Known allergy or other adverse reaction to calcipotriene or other vitamin D analogs; or to any component of the investigational formulatio...
U0267 Foam is an investigational small molecule being studied for the treatment of plaque-type psoriasis. It is a topical foam formulation developed by GSK plc. The drug is currently in Phase 3 clinical development, though the specific trial has been completed. It is not yet approved by regulatory authorities.
U0267 Foam is a small molecule developed for topical use in psoriasis. The specific molecular target of U0267 Foam has not been disclosed in available clinical trial information. The drug is being evaluated for its efficacy and safety in treating plaque-type psoriasis, a chronic inflammatory skin condition.
U0267 Foam is being developed by GSK plc, a global biopharmaceutical company listed on the London Stock Exchange under the ticker GSK. The company is conducting clinical research to evaluate the drug's potential as a treatment for plaque-type psoriasis.
U0267 Foam is in Phase 3 clinical development. A Phase 3 study, NCT00689481, has been completed. This trial was a randomized, double-blind, placebo-controlled study that enrolled 323 participants with plaque-type psoriasis. The drug remains investigational and has not received regulatory approval.
U0267 Foam has one completed Phase 3 clinical trial, NCT00689481, titled 'Study to Compare U0267 Against Vehicle in Subjects With Plaque-type Psoriasis Two of Two Phase 3 Studies.' This randomized, double-blind, placebo-controlled study enrolled 323 participants in the United States, including individuals aged 12 years and older.
U0267 Foam is the name used in clinical trials for this investigational product. No alternative names have been disclosed in the available trial information. The drug is being studied specifically as a topical foam for plaque-type psoriasis and is not known to be marketed under any other name.